Pulmatrix (PULM) Q2 Revenue Falls 100%

Pulmatrix (Nasdaq: PULM) reported 2Q 2026 results and updated investors on its proposed merger with privately held Eos SENOLYTIX. Pulmatrix filed an S-4 and said the deal is expected to close in 3Q 2026. It raised $1.0 million via a private placement. Cash was $2.2 million at June 30, 2026.

Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX Framingham, Mass., August 13, 2026 – Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharm

Capstone Copper (CSCCF) plans to invest $3B in Chile's Atacama region to double copper production by 2031, according to Chile's mining ministry. The investment includes $2.3B for the Santo Domingo project and $220M for other initiatives.

CME Group reported a record $9.2 billion in Brazilian real futures contracts traded following Brazil's election, 11 times the year-to-date average. Paul Houston, Global Head of FX Products, noted clients used the platform to manage risk outside Brazilian trading hours. The company offers derivatives across various asset classes.

Stifel reiterated a Buy rating and $157 price target for Incyte (INCY) after positive cancer drug trial data. The stock trades at $115.77 with a P/E of 14.66 and PEG of 0.18. Analysts highlight INCB734's potential in pancreatic and colorectal cancer, with key data expected in 2027-2028. Other analysts also commented on Incyte's pipeline, with varied price targets and ratings.

Argus Research downgraded Abbott Laboratories (ABT) to Hold from Buy, citing the company's reduced full-year growth outlook. ABT shares traded lower following the downgrade.